Close Menu

NEW YORK – Investment firm Cowen downgraded Myriad Genetics' stock to a market perform rating from outperform expressing "lower overall conviction" that the firm would be able to meet its revenue expectations for the fiscal year.

The investment bank also trimmed its stock price target for Myriad to $30 per share from the previous target of $37 per share.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.